Lipitor, Zocor Pediatric Safety Surveillance Needs More Time, FDA Cmte. Says
Executive Summary
Pediatric safety surveillance for Pfizer's Zoloft and Lipitor should continue for another year, the Anti-Infective Drugs Pediatric Advisory Subcommittee advised FDA during a June 12 meeting
You may also be interested in...
Zyrtec Mix-Ups With Zantac Cited In FDA Pediatric Adverse Events Review
FDA is working on steps to minimize medication errors for Pfizer's Zyrtec due to confusion with GlaxoSmithKline's Zantac
Zyrtec Mix-Ups With Zantac Cited In FDA Pediatric Adverse Events Review
FDA is working on steps to minimize medication errors for Pfizer's Zyrtec due to confusion with GlaxoSmithKline's Zantac
Pediatric Adverse Event Analysis By FDA Will Project Incidence Rates
FDA plans to use hospital use data to project use among the in-patient pediatric population to determine incidence rates for adverse event reports mandated by the Best Pharmaceuticals for Children Act